Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL consortium

Zsofia Kote-Jarai; Douglas F Easton; Janet L Stanford; Elaine A Ostrander; Johanna Schleutker; Sue A Ingles; Daniel Schaid; Stephen Thibodeau; Thilo Doerk; David Neal; Angela Cox; Christiane Maier; Walter Vogel; Michelle Guy; Kenneth Muir; Artitaya Lophatananon; Mary-Anne Kedda; Amanda Spurdle; Suzanne Steginga; Esther M John; Graham Giles; John Hopper; Pierre O Chappuis; Pierre Hutter; William D Foulkes; Nancy Hamel; Claudia A Salinas; Joseph S Koopmeiners; Danielle M Karyadi; Bo Johanneson; Tiina Wahlfors; Teuvo L Tammela; Mariana C Stern; Roman Corral; Shannon K McDonnell; Peter Schuermann; Andreas Meyer; Rainer Kuefer; Daniel A Leongamornlert; Malgorzata Tymrakiewicz; Jo-fen Liu; Tracy O'Mara; RA Frank Gardiner; Joanne Aitken; Amit D Joshi; Gianluca Severi; Dallas R English; Melissa Southey; Stephen M Edwards; Ali Amin Al Olama; Rosalind A Eeles

Journal article

Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL consortium

Zsofia Kote-Jarai, Douglas F Easton, Janet L Stanford, Elaine A Ostrander, Johanna Schleutker, Sue A Ingles, Daniel Schaid, Stephen Thibodeau, Thilo Doerk, David Neal, Angela Cox, Christiane Maier, Walter Vogel, Michelle Guy, Kenneth Muir, Artitaya Lophatananon, Mary-Anne Kedda, Amanda Spurdle, Suzanne Steginga, Esther M John Show all

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION | AMER ASSOC CANCER RESEARCH | Published : 2008

DOI: 10.1158/1055-9965.EPI-08-0317

Abstract

A recent genome-wide association study found that genetic variants on chromosomes 3, 6, 7, 10, 11, 19 and X were associated with prostate cancer risk. We evaluated the most significant single-nucleotide polymorphisms (SNP) in these loci using a worldwide consortium of 13 groups (PRACTICAL). Blood DNA from 7,370 prostate cancer cases and 5,742 male controls was analyzed by genotyping assays. Odds ratios (OR) associated with each genotype were estimated using unconditional logistic regression. Six of the seven SNPs showed clear evidence of association with prostate cancer (P = 0.0007-P = 10(-17)). For each of these six SNPs, the estimated per-allele OR was similar to those previously reported ..

View full abstract

University of Melbourne Researchers

Graham Giles Author Melbourne School of Population and Global Health

John Hopper Author Melbourne School of Population and Global Health

Dallas English Author Melbourne School of Population and Global Health

Melissa Southey Author Clinical Pathology

Gianluca Severi Author Melbourne School of Population and Global Health

Related Projects (1)

Epidemiology of chronic disease, health interventions and DNA studies

nan

Grants

Awarded by Cancer Research UK

Awarded by National Health and Medical Research Council, Australia

Awarded by Health Technology Assessment Programme

Awarded by Medical Research Council of England

Awarded by U.S. Department of Defense

Awarded by National Cancer Institute

Awarded by U.S. Department of Defense, U.S Army

Awarded by U.S. National Cancer Institute

Awarded by California Cancer Research

Awarded by Academy of Finland

Awarded by NIH

Awarded by NATIONAL CANCER INSTITUTE

Awarded by NATIONAL HUMAN GENOME RESEARCH INSTITUTE

Awarded by Medical Research Council

Funding Acknowledgements

Cancer Research UK grant C5047/A3354. We would also like to thank the following for funding support: The Institute of Cancer Research and The Everyman Campaign, The Prostate Cancer Research Foundation, Prostate Research Campaign UK, The National Cancer Research Network UK, The National Cancer Research Institute UK, grants from the National Health and Medical Research Council, Australia (209057, 251533, 450104, 390130), VicHealth, The Cancer Council Victoria, The Cancer Council Queensland, The Whitten Foundation, and Tattersall's. E.A. Ostrander, D.M. Karvadi, and B. Johanneson acknowledge the intramural Program of the National Human Genome Research Institute for their support. The ProtecT study is ongoing and is funded by the Health Technology Assessment Programme (projects 96/20/06 and 96/20/99). The ProtecT trial and its linked ProMPT and CAP (Comparison Arm for ProtecT) Studies are supported by Department of Health, England; Cancer Research UK grant C522/A8649, Medical Research Council of England grant G0500966, ID 75466 and The National Cancer Research Institute, UK. DNA extraction in ProtecT was supported by U.S. Department of Defense award W81XWH-04-1-0280. The Fred Hutchinson Cancer Research Center work was supported by grants CA56678, CA92579, and CA97186 from the National Cancer Institute, NIH, with additional support from the Fred Hutchinson Cancer Research Center. Ongoing work in Montreal has been funded in turn by the U.S. Department of Defense (U.S. Army Grant DAMD17-00-1-0033; Principal Investigator W.D. Foulkes), the Canadian Genetic Diseases Network, and the NIH The study, in Switzerland was supported by the U.S. Army Grant DAMD17-00-1-0033 (Principal Investigator: W.D. Foulkes) and a grant from the Institut Central des Hopitaux Valaisans, Sion, Switzerland. The Mayo group was supported by the U.S. National Cancer Institute (R01CA72818). The University of Southern California study was supported by the U.S. National Cancer Institute (R01CAS4979) and by the California Cancer Research Program (99-00524V-102-58). The San Francisco study was supported by the California Cancer Research Fund (99-00527V-10182). The Tampere (Finland) study was supported by the Academy of Finland grant 118413, The Finnish Career Organisitions, Sigrid Juselius Foundation, Reino Lahtikari Foundation, and The Medical Research Fund of Tampere University Hospital. The Hannover Prostate Cancer Study was supported by an intramural Hannelore-Munke stipend to A. Meyer. The Fred Hutchinson Cancer Research Center, Mayo, Melbourne Collaborative Cohort Study, Montreal, Tampere, U.K. Genetic Prostate Cancer Study and Ulm groups are part of the International Consortium for Prostate Cancer Genetics supported by NIH grant U01 CA089600-04.